Moneycontrol
Get App
Last Updated : Jan 08, 2013 05:17 PM IST | Source: Moneycontrol.com

See pharma sector's margins to dip 314 bps in 3QFY13: Angel

Angel Broking has come out with earning expectations for pharmaceutical sector for the October-December quarter of 2012. The research firm expects the Indian pharma sector to post lackluster numbers for 3QFY2013 on the sales front.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Angel Broking has come out with earning expectations for pharmaceutical sector for the October-December quarter of 2012. The research firm expects the Indian pharma sector to post lackluster numbers for 3QFY2013 on the sales front.

Angel Broking Q3FY2013 expectations for pharmaceutical sector:

We expect our coverage universe to register a 2.0% YoY flat top-line growth. The muted top-line growth during the period would be on account of last corresponding period's base. On the operating front, the margins are expected to decline by 314bp. This along with higher taxation is expected to lead the companies in our coverage universe to post a dip of 1.6% in net profit during the period. Amongst large caps, Sun Pharma is expected to post an 11.1%YoY sales growth. Cipla is expected to post a net sales growth of 18.3%. Other players, namely Lupin and Cadila Healthcare are expected to report a growth of 17.2% and 15.3%, respectively. DRL and Ranbaxy Laboratories on the other hand are expected to post a decline in their top-line by around 2.5% and 32.5% respectively. Amongst small caps, Indoco Remedies is expected to post a 30.8% YoY growth. Amongst the MNC pack, Sanofi India is likely to post a 15.1% YoY growth in net sales, while Glaxo Smithkline Pharmaceuticals is expected to post a 20.1% YoY growth in sales.

Outlook and Valuation

With an expected CAGR of ~20% in earnings over FY2012-14E for our universe of pharma stocks, we remain overweight on the sector maintaining a positive future outlook and earnings growth. Though the stocks have witness a good upsides, in near time, leavening little upsides for stocks in near time. However, given the opportunities, in the sector we maintain our long-term buy on the stocks.

CompanyNet SalesNet Profit
3QFY13E% Chg3QFY13E% Chg
Alembic Pharma42611.729-34.8
Aurobindo1,39210.1152-
Cadila1,55915.318221.7
Cipla2,02418.340449.7
Dishman31518.72441.8
Dr Reddys2,700-2.5339-33.9
Glaxo#68020.1132-10.2
Indoco Rem.18530.819124
Ipca73121.593-10.6
Lupin2,10017.225910.1
Ranbaxy Lab#2,525-32.5274-36.1
Sanofi India#38915.15964.7
Sun Pharma2,38311.1584-12.6

 

 

 

 

 

 

 

 

 

 

 

 

 

Note: Price as on December 31, 2012; Our numbers do not include MTM on foreign debt. # 4QCY2012

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.



Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.
First Published on Jan 8, 2013 05:10 pm
Sections
Follow us on